44 Wealth Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$495K Sell
3,161
-244
-7% -$36.6K 0.16% 140
2026
Q1
$520K Buy
3,405
+1,004
+42% +$154K 0.18% 140
2025
Q4
$331K Buy
+2,401
New +$314K 0.11% 163

Other funds holding NVS

44 Wealth Management's NVS Position: Q2 2026 in Review

44 Wealth Management reduced its Novartis (NVS) stake by 7.2% in Q2 2026, selling an estimated $36.6K and leaving 3,161 shares worth $495K. The position accounts for 0.16% of the portfolio, ranked #140.

44 Wealth Management first reported a position in NVS in Q4 2025 and has held it in 3 quarters since. The position peaked at $520K in Q1 2026. 1,620 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • 44 Wealth Management held 3,161 shares of Novartis worth $495K as of Q2 2026.
  • 44 Wealth Management sold 244 Novartis shares in Q2 2026, an estimated $36.6K.
  • Novartis made up 0.16% of 44 Wealth Management's portfolio in Q2 2026, its #140 holding.
  • 44 Wealth Management first reported a position in Novartis in Q4 2025 and has held it in 3 quarters since.
  • 44 Wealth Management's Novartis position peaked at $520K in Q1 2026.
  • 1,620 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on 44 Wealth Management's 13F filing for Q2 2026, filed 14 Aug 2026.